Short Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7%

InflaRx (NASDAQ:IFRX) was the recipient of a significant drop in short interest in January. As of January 31st, there was short interest totalling 415,200 shares, a drop of 13.7% from the January 15th total of 481,300 shares. Based on an average trading volume of 305,500 shares, the days-to-cover ratio is presently 1.4 days.

InflaRx Stock Down 25.9 %

Shares of NASDAQ IFRX traded down $0.70 during mid-day trading on Friday, hitting $2.00. The stock had a trading volume of 4,566,637 shares, compared to its average volume of 193,817. InflaRx has a 1 year low of $1.16 and a 1 year high of $2.82. The business has a 50 day moving average price of $2.42 and a two-hundred day moving average price of $1.91.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Two Sigma Securities LLC purchased a new position in shares of InflaRx in the fourth quarter worth $28,000. Walleye Capital LLC purchased a new position in shares of InflaRx in the fourth quarter worth $51,000. Geode Capital Management LLC increased its stake in shares of InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock worth $119,000 after buying an additional 11,900 shares during the period. Commonwealth Equity Services LLC increased its stake in shares of InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after buying an additional 19,000 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in InflaRx during the 4th quarter valued at $1,576,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of InflaRx in a research note on Thursday, January 16th.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.